Calandrini Vania, Rossetti Giulia, Arnesano Fabio, Natile Giovanni, Carloni Paolo
Computational Biomedicine, Institute for Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich, Jülich, Germany.
Computational Biomedicine, Institute for Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich, Jülich, Germany; Jülich Supercomputing Centre (JSC), Forschungszentrum Jülich, Jülich, Germany; Department of Oncology, Hematology and Stem Cell Transplantation, RWTH Aachen University, Aachen, Germany.
J Inorg Biochem. 2015 Dec;153:231-238. doi: 10.1016/j.jinorgbio.2015.10.001. Epub 2015 Oct 8.
Cisplatin, cis-diamminedichlorido-platinum(II), is an important therapeutic tool in the struggle against different tumors, yet it is plagued with the emergence of resistance mechanisms after repeated administrations. This hampers greatly its efficacy. Overcoming resistance problems requires first and foremost an integrated and systematic understanding of the structural determinants and molecular recognition processes involving the drug and its cellular targets. Here we review a strategy that we have followed for the last few years, based on the combination of modern tools from computational chemistry with experimental biophysical methods. Using hybrid Quantum Mechanics/Molecular Mechanics (QM/MM) simulations, validated by spectroscopic experiments (including NMR, and CD), we have worked out for the first time at atomic level the structural determinants in solution of platinated cellular substrates. These include the copper homeostasis proteins Ctr1, Atox1, and ATP7A. All of these proteins have been suggested to influence the pre-target resistance mechanisms. Furthermore, coupling hybrid QM/MM simulations with classical Molecular Dynamics (MD) and free energy calculations, based on force field parameters refined by the so-called "Force Matching" procedure, we have characterized the structural modifications and the free energy landscape associated with the recognition between platinated DNA and the protein HMGB1, belonging to the chromosomal high-mobility group proteins HMGB that inhibit the repair of platinated DNA. This may alleviate issues relative to on-target resistance process. The elucidation of the mechanisms by which tumors are sensitive or refractory to cisplatin may lead to the discovery of prognostic biomarkers. The approach reviewed here could be straightforwardly extended to other metal-based drugs.
顺铂,顺 - 二氨二氯铂(II),是对抗不同肿瘤的重要治疗工具,但在反复给药后会出现耐药机制,这极大地阻碍了其疗效。克服耐药问题首先需要对涉及药物及其细胞靶点的结构决定因素和分子识别过程有全面系统的了解。在此,我们回顾过去几年我们所采用的一种策略,该策略基于将计算化学的现代工具与实验生物物理方法相结合。通过光谱实验(包括核磁共振和圆二色光谱)验证,使用混合量子力学/分子力学(QM/MM)模拟,我们首次在原子水平上确定了铂化细胞底物在溶液中的结构决定因素。这些因素包括铜稳态蛋白Ctr1、Atox1和ATP7A。所有这些蛋白都被认为会影响靶点前的耐药机制。此外,基于通过所谓的“力匹配”程序优化的力场参数,将混合QM/MM模拟与经典分子动力学(MD)和自由能计算相结合,我们表征了与铂化DNA和蛋白HMGB1之间的识别相关的结构修饰和自由能景观,HMGB1属于染色体高迁移率族蛋白HMGB,它会抑制铂化DNA的修复。这可能会缓解与靶点耐药过程相关的问题。阐明肿瘤对顺铂敏感或耐药的机制可能会导致发现预后生物标志物。这里所回顾的方法可以直接扩展到其他金属基药物。